Independent. No ads, no affiliate links, no vendor payment. Reviewed weekly Editorial policy Newsletter

Home›The Library›Crovalimab

Crovalimab (Piasky)

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 16 September 2026Funding No ads, no affiliate links, no vendor payment

Crovalimab is a third complement-C5 antibody for paroxysmal nocturnal hemoglobinuria, completing this site's anti-C5 cluster alongside eculizumab and ravulizumab — the two drugs its own pivotal trials were built to match. FDA-approved 20 June 2024, it binds a different part of C5 than its predecessors, engineered specifically to allow low-volume, once-monthly subcutaneous self-injection at home instead of a recurring clinic infusion. It matched eculizumab on the same efficacy measures those older drugs were approved on, and it carries a genuinely distinct, mechanism-specific risk the older drugs don't: patients switching from eculizumab can form transient drug-drug-target complexes that caused mild-to-moderate vasculitic skin reactions in a real minority of trial patients.

On this page
  1. A third way to block C5, engineered for self-injection
  2. COMMODORE 1 and 2: matching eculizumab, with fewer clinic visits
  3. A real, mechanism-specific risk: switching from eculizumab
  4. The same class-wide meningococcal risk
  5. Current status

In brief

Should you care? Relevant if you're comparing complement-C5 treatment options for PNH alongside this site's eculizumab & ravulizumab page — crovalimab is a third, distinct antibody against the same target, engineered specifically for home self-injection instead of clinic infusion.

The short version

  • What it is: a humanized monoclonal antibody against complement C5, engineered by Chugai Pharmaceutical and developed by Roche/Genentech, that binds a different C5 epitope than eculizumab and is recycled through the neonatal Fc receptor for a long enough half-life to allow monthly, low-volume subcutaneous dosing.
  • Evidence: two randomized, active-controlled Phase 3 trials (COMMODORE 1 and 2, combined 293 patients) found crovalimab noninferior to eculizumab on transfusion avoidance and hemolysis control.
  • The real, distinct risk: because crovalimab binds a different C5 epitope than eculizumab, patients switching between the two can form transient drug-target-drug complexes that trigger a Type III hypersensitivity reaction — seen in 18% of 185 pooled switching patients across the COMMODORE trials, most mild-to-moderate and resolving within weeks.

A third way to block C5, engineered for self-injection

This site's eculizumab & ravulizumab page describes the first two FDA-approved antibodies against complement protein C5, both requiring recurring clinic-based IV infusions. Crovalimab, engineered by Chugai Pharmaceutical and developed and marketed by Roche/Genentech, is a third: a humanized monoclonal antibody that binds a different site on C5 than eculizumab does (a beta-chain epitope rather than eculizumab's alpha-chain epitope), blocking the same terminal step in the complement cascade. Its real engineering goal wasn't a new mechanism so much as a new format: crovalimab uses pH-dependent, recycling antibody technology — binding C5 tightly at physiological pH, then releasing it in the acidic environment inside a cell and being recycled back into circulation via the neonatal Fc receptor rather than degraded — to reach a long enough effective half-life for low-volume, weight-tiered subcutaneous dosing every 4 weeks, administered by the patient at home after an initial loading phase. The FDA approved it as Piasky on 20 June 2024 for patients 13 years and older weighing at least 40 kg with paroxysmal nocturnal hemoglobinuria (PNH); the European Commission approved it on 27 August 2024 for ages 12 and older at the same weight threshold, calling it the first monthly subcutaneous treatment for PNH in the EU.

COMMODORE 1 and 2: matching eculizumab, with fewer clinic visits

Crovalimab's approval rested on two randomized, open-label, active-controlled Phase 3 trials against eculizumab. COMMODORE 2 enrolled 204 complement-inhibitor-naive PNH patients (135 to crovalimab, 69 to continued eculizumab); at 25 weeks, transfusion avoidance was 65.7% with crovalimab versus 68.1% with eculizumab (weighted difference -2.8%, 95% CI -15.7 to 11.1, meeting the trial's prespecified non-inferiority margin), and hemolysis control was 79.3% versus 79.0% (Röth A, Kulasekararaj AG, et al., "Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition," Am J Hematol 2024;99(9):1768-1777, PMID 38884175, DOI: 10.1002/ajh.27412).1 COMMODORE 1 enrolled a different population — 89 patients already stable on eculizumab (45 switched to crovalimab, 44 continued eculizumab) — and found comparable hemolysis control between the two arms over the same 24-week primary period (Röth A, Kulasekararaj AG, et al., "Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria," Am J Hematol 2024;99(9):1757-1767, PMID 38924124, DOI: 10.1002/ajh.27413).2 Across both trials, patient-reported preference data favored crovalimab's dosing format — a real, if secondary, practical advantage over an efficacy profile that was designed and shown to match, not beat, eculizumab's.

A real, mechanism-specific risk: switching from eculizumab

Drug-target-drug complexes, not a class-wide side effect

Because crovalimab and eculizumab bind different, non-overlapping epitopes on the same C5 molecule, a patient switching from one to the other can end up with both antibodies bound to the same C5 molecule at once, forming a three-part "drug-target-drug complex" (DTDC) that neither drug forms on its own. Piasky's FDA label carries a specific warning for this: patients switching between crovalimab and another C5 inhibitor (eculizumab or ravulizumab) are at risk of a Type III hypersensitivity reaction — immune-complex-driven symptoms that can include rash, joint pain, fever, muscle aches and, less often, kidney abnormalities. A pooled safety analysis of 185 patients who switched to crovalimab from eculizumab or ravulizumab across the COMMODORE trials found this reaction in 18% of them, with a median time to onset of about 1.6 weeks and median time to resolution of about 1.9 weeks; most cases were mild-to-moderate (grade 1-2), with grade 3 reactions in about 7% of the switching group. This is a real, mechanism-specific finding distinct from ordinary infusion or injection-site reactions, and specific to switching between C5 inhibitors that bind different epitopes rather than to crovalimab treatment generally — not a reason to avoid crovalimab as a first-line choice, but a genuine, drug-specific consideration a treating hematologist manages and monitors around any switch.

The same class-wide meningococcal risk

Like eculizumab and ravulizumab, crovalimab carries a boxed warning for serious and potentially fatal Neisseria meningitidis infection — a direct, mechanistic consequence of blocking terminal complement activity, the same immune pathway that normally helps clear that bacterium. Patients must complete or update meningococcal vaccination against serogroups A, C, W, Y and B at least 2 weeks before the first dose wherever possible, per current ACIP recommendations, and crovalimab is available only through the Piasky REMS program — the same structural safety requirement this site's eculizumab & ravulizumab and zilucoplan pages describe for every other approved C5-pathway drug. Vaccination reduces but does not eliminate the risk; life-threatening meningococcal infections have occurred in vaccinated and unvaccinated complement-inhibitor patients alike.

Current status

Piasky remains FDA- and EU-approved for PNH and is actively marketed by Roche/Genentech, positioned directly against eculizumab and ravulizumab as a self-administered, once-monthly subcutaneous alternative to clinic-based infusion. As a recently approved biologic for a specific, narrow rare-disease indication, it carries no wellness, off-label or grey-market interest of any kind — the same pattern this site's other complement-inhibitor pages describe.

References

  1. FDA approval of Piasky (crovalimab-akkz, BLA 761388, Genentech), 20 June 2024, for PNH in patients 13 years and older weighing at least 40 kg; European Commission approval, 27 August 2024, for ages 12 and older at the same weight threshold.
  2. Röth A, Kulasekararaj AG, Kim JS, et al., "Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition," Am J Hematol 2024;99(9):1768-1777, PMID 38884175, DOI: 10.1002/ajh.27412 — 204 patients; transfusion avoidance 65.7% (crovalimab) vs. 68.1% (eculizumab); hemolysis control 79.3% vs. 79.0%.
  3. Röth A, Kulasekararaj AG, Kim JS, et al., "Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria," Am J Hematol 2024;99(9):1757-1767, PMID 38924124, DOI: 10.1002/ajh.27413 — 89 patients switched from or continued on eculizumab.
  4. Piasky (crovalimab-akkz) FDA-approved prescribing information (Genentech), Warnings and Precautions section on Type III hypersensitivity reactions from drug-target-drug complex (DTDC) formation in patients switching between crovalimab and another C5 inhibitor; pooled safety analysis of 185 patients switching to crovalimab from eculizumab or ravulizumab across the COMMODORE 1 and 2 trials, reporting transient immune-complex reactions in 18% (median onset ~1.6 weeks, median resolution ~1.9 weeks, grade 3 in ~7%) — cross-checked across the FDA label, DailyMed, and published COMMODORE pooled-safety reporting. Piasky boxed warning for meningococcal infection and REMS program requirements, per the same FDA-approved prescribing information, current as of this review.